Merck ordered to halt new Keytruda formulation in several European countries
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
A Dutch court found that Merck infringed a Halozyme Therapeutics patent and ordered it to stop making and marketing subcutaneous Keytruda in France, Italy, Sweden, Switzerland and the Netherlands. The existing intravenous cancer treatment remains available and is unaffected.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu